{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:27:30Z","timestamp":1772119650428,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03629-9","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T06:16:29Z","timestamp":1751004989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of ocular sarcoidosis. Study of 65 patients from a series of 342 from a university hospital in northern Spain"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2401-3781","authenticated-orcid":false,"given":"Fabricio","family":"Benavides-Villanueva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6903-8707","authenticated-orcid":false,"given":"Jorge J.","family":"Gait\u00e1n-Valdiz\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5616-371X","authenticated-orcid":false,"given":"Ra\u00fal","family":"Fern\u00e1ndez-Ram\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-6633","authenticated-orcid":false,"given":"Jos\u00e9 L.","family":"Mart\u00edn-Varillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0230-381X","authenticated-orcid":false,"given":"Armin","family":"Mobarak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3682-0142","authenticated-orcid":false,"given":"Jos\u00e9","family":"Cifri\u00e1n-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-234X","authenticated-orcid":false,"given":"Rosal\u00eda","family":"Demetrio-Pablo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-853X","authenticated-orcid":false,"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"3629_CR1","unstructured":"American Thoracic Society (ATS). American Thoracic Society Medical section of the American Lung Association Statement on Sarcoidosis This Joint Statement of the American Thoracic Society (ATS), The European Respiratory Society (ERS) and the World Association Of Sarcoidosis and other Graanulomatous Disorders (WASOG). 1999."},{"key":"3629_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093194","author":"S Giorgiutti","year":"2023","unstructured":"Giorgiutti S, Jacquot R, El Jammal T, Bert A, Jamilloux Y, Kodjikian L et al (2023) Sarcoidosis-related uveitis: a review. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12093194","journal-title":"J Clin Med"},{"key":"3629_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1594\/ecr2015\/C-2049","volume":"7","author":"S Palmucci","year":"2016","unstructured":"Palmucci S, Emanuele Torrisi S, Carmelo Caltabiano D, Puglisi S, Lentini V, Grassedonio E et al (2016) Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay. Insights Imaging 7:571\u2013587. https:\/\/doi.org\/10.1594\/ecr2015\/C-2049","journal-title":"Insights Imaging"},{"key":"3629_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.mcna.2011.08.004","volume":"95","author":"N Hamzeh","year":"2011","unstructured":"Hamzeh N (2011) Sarcoidosis. Med Clin North Am 95:1223\u20131234. https:\/\/doi.org\/10.1016\/j.mcna.2011.08.004","journal-title":"Med Clin North Am"},{"key":"3629_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.iac.2012.08.005","volume":"32","author":"DA Culver","year":"2012","unstructured":"Culver DA (2012) Sarcoidosis. Immunol Allergy Clin North Am 32:487\u2013511. https:\/\/doi.org\/10.1016\/j.iac.2012.08.005","journal-title":"Immunol Allergy Clin North Am"},{"key":"3629_CR6","volume-title":"Sarcoidosis. The Lancet","author":"D Valeyre","year":"2014","unstructured":"Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, M\u00fcller-Quernheim J (2014) Sarcoidosis. The Lancet, vol 383. Elsevier"},{"key":"3629_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-2007-970335","volume":"28","author":"MA Judson","year":"2007","unstructured":"Judson MA (2007) Extrapulmonary sarcoidosis. Semin Respir Crit Care Med 28:83\u2013101. https:\/\/doi.org\/10.1055\/s-2007-970335","journal-title":"Semin Respir Crit Care Med"},{"key":"3629_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040766","author":"P S\u00e8ve","year":"2021","unstructured":"S\u00e8ve P, Pacheco Y, Durupt F, Jamilloux Y, Gerfaud-Valentin M, Isaac S et al (2021) Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells. https:\/\/doi.org\/10.3390\/cells10040766","journal-title":"Cells"},{"key":"3629_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/bjophthalmol-2016-309767","volume":"101","author":"C Rochepeau","year":"2017","unstructured":"Rochepeau C, Jamilloux Y, Kerever S, Febvay C, Perard L, Broussolle C et al (2017) Long-term visual and systemic prognoses of 83 cases of biopsy-proven sarcoid uveitis. Br J Ophthalmol 101:856\u2013861. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309767","journal-title":"Br J Ophthalmol"},{"key":"3629_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2012.04.004","author":"B Bodaghi","year":"2012","unstructured":"Bodaghi B, Touitou V, Fardeau C, Chapelon C, LeHoang P (2012) Ocular sarcoidosis. Presse Medicale. https:\/\/doi.org\/10.1016\/j.lpm.2012.04.004","journal-title":"Presse Medicale"},{"key":"3629_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ICU.0b013e328358c7a6","volume":"23","author":"KA Umur","year":"2012","unstructured":"Umur KA, Tayfun B, Oguzhan O (2012) Different ophthalmologic manifestations of sarcoidosis. Curr Opin Ophthalmol 23:477\u2013484. https:\/\/doi.org\/10.1097\/ICU.0b013e328358c7a6","journal-title":"Curr Opin Ophthalmol"},{"key":"3629_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/ICU.0b013e32833eae4d","volume":"21","author":"YL Phillips","year":"2010","unstructured":"Phillips YL, Eggenberger ER (2010) Neuro-ophthalmic sarcoidosis. Curr Opin Ophthalmol 21:423\u2013429. https:\/\/doi.org\/10.1097\/ICU.0b013e32833eae4d","journal-title":"Curr Opin Ophthalmol"},{"key":"3629_CR13","doi-asserted-by":"crossref","unstructured":"Crick RP, Hoyle C, Smellie H (1961) The eyes in Sarcoidosis.","DOI":"10.1136\/bjo.45.7.461"},{"key":"3629_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccm.2015.08.009","volume":"36","author":"S Pasadhika","year":"2015","unstructured":"Pasadhika S, Rosenbaum JT (2015) Ocular sarcoidosis. Clin Chest Med 36:669\u2013683. https:\/\/doi.org\/10.1016\/j.ccm.2015.08.009","journal-title":"Clin Chest Med"},{"key":"3629_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/08820530500231938","volume":"20","author":"AA Bonfioli","year":"2005","unstructured":"Bonfioli AA, Orefice F (2005) Sarcoidosis. Semin Ophthalmol 20:177\u2013182. https:\/\/doi.org\/10.1080\/08820530500231938","journal-title":"Semin Ophthalmol"},{"key":"3629_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/08820538.2016.1206576","volume":"33","author":"J Paovic","year":"2018","unstructured":"Paovic J, Paovic P, Sredovic V, Jovanovic S (2018) Clinical manifestations, complications and treatment of ocular sarcoidosis: correlation between visual efficiency and macular edema as seen on optical coherence tomography. Semin Ophthalmol 33:202\u2013209. https:\/\/doi.org\/10.1080\/08820538.2016.1206576","journal-title":"Semin Ophthalmol"},{"key":"3629_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/art.39472","volume":"68","author":"E Crickx","year":"2016","unstructured":"Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T et al (2016) intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a french nationwide study of ninety-two patients. Arthritis and Rheumatology 68:702\u2013712. https:\/\/doi.org\/10.1002\/art.39472","journal-title":"Arthritis and Rheumatology"},{"key":"3629_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.disamonth.2009.05.002","volume":"55","author":"J Holmes","year":"2009","unstructured":"Holmes J, Lazarus A (2009) Sarcoidosis: extrathoracic manifestations. Dis Mon 55:675\u2013692. https:\/\/doi.org\/10.1016\/j.disamonth.2009.05.002","journal-title":"Dis Mon"},{"key":"3629_CR19","doi-asserted-by":"crossref","unstructured":"Jabs DA, Johns CJ (1986) Ocular Involvement in Chronic Sarcoidosis. vol. 102.","DOI":"10.1016\/0002-9394(86)90001-2"},{"key":"3629_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-13-39","author":"S Tempest-Roe","year":"2013","unstructured":"Tempest-Roe S, Joshi L, Dick AD, Taylor SR (2013) Local therapies for inflammatory eye disease in translation: Past, present and future. BMC Ophthalmol. https:\/\/doi.org\/10.1186\/1471-2415-13-39","journal-title":"BMC Ophthalmol"},{"key":"3629_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/164692","author":"M Cabrera","year":"2014","unstructured":"Cabrera M, Yeh S, Albini TA (2014) Sustained-release corticosteroid options. J Ophthalmol. https:\/\/doi.org\/10.1155\/2014\/164692","journal-title":"J Ophthalmol"},{"key":"3629_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/09273948.2013.767353","volume":"21","author":"SS Salek","year":"2013","unstructured":"Salek SS, Leder HA, Butler NJ, Gan TJ, Dunn JP, Thorne JE (2013) Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm 21:257\u2013263. https:\/\/doi.org\/10.3109\/09273948.2013.767353","journal-title":"Ocul Immunol Inflamm"},{"key":"3629_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.22336\/rjo.2018.16","volume":"61","author":"I Duica","year":"2018","unstructured":"Duica I, Voinea L-M, Mitulescu C, Istrate S, Coman I-C, Ciuluvica R (2018) The use of biologic therapies in uveitis. Rom J Ophthalmol 61:105\u2013113. https:\/\/doi.org\/10.22336\/rjo.2018.16","journal-title":"Rom J Ophthalmol"},{"key":"3629_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ccm.2008.03.012","volume":"29","author":"RP Baughman","year":"2008","unstructured":"Baughman RP, Costabel U, du Bois RM (2008) Treatment of Sarcoidosis. Clin Chest Med 29:533\u2013548. https:\/\/doi.org\/10.1016\/j.ccm.2008.03.012","journal-title":"Clin Chest Med"},{"key":"3629_CR25","doi-asserted-by":"crossref","unstructured":"Iannuzzi MC, Rybicki BA, Teirstein AS. (2007) Sarcoidosis. vol. 357. 2007.","DOI":"10.1056\/NEJMra071714"},{"key":"3629_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.05.008","author":"S Pasadhika","year":"2009","unstructured":"Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT et al (2009) Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2009.05.008","journal-title":"Am J Ophthalmol"},{"key":"3629_CR27","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","volume":"121","author":"SR Rathinam","year":"2014","unstructured":"Rathinam SR, Babu M, Thundikandy R, Kanakath A, Nardone N, Esterberg E et al (2014) A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology 121:1863\u20131870. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.023","journal-title":"Ophthalmology"},{"key":"3629_CR28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","volume":"117","author":"RO Ka\u00e7maz","year":"2010","unstructured":"Ka\u00e7maz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB et al (2010) Cyclosporine for ocular inflammatory diseases. Ophthalmology 117:576\u2013584. https:\/\/doi.org\/10.1016\/j.ophtha.2009.08.010","journal-title":"Ophthalmology"},{"key":"3629_CR29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/nejmoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, Nguyen QD, Thorne JE, Kestelyn P et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375:932\u2013943. https:\/\/doi.org\/10.1056\/nejmoa1509852","journal-title":"N Engl J Med"},{"key":"3629_CR30","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet 388:1183\u20131192. https:\/\/doi.org\/10.1016\/S0140-6736(16)31339-3","journal-title":"The Lancet"},{"key":"3629_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","volume":"45","author":"L Riancho-Zarrabeitia","year":"2015","unstructured":"Riancho-Zarrabeitia L, Calvo-R\u00edo V, Blanco R, Mesquida M, Adan AM, Herreras JM et al (2015) Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum 45:361\u2013368. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.05.010","journal-title":"Semin Arthritis Rheum"},{"key":"3629_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","volume":"97","author":"EB Suhler","year":"2013","unstructured":"Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA et al (2013) Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 97:481\u2013486. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302292","journal-title":"Br J Ophthalmol"},{"key":"3629_CR33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9057","author":"OD Ogbue","year":"2020","unstructured":"Ogbue OD, Malhotra P, Akku R, Jayaprakash T, Khan S (2020) Biologic therapies in sarcoidosis and uveitis: a review. Cureus. https:\/\/doi.org\/10.7759\/cureus.9057","journal-title":"Cureus"},{"key":"3629_CR34","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","volume":"68","author":"H Vallet","year":"2016","unstructured":"Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L et al (2016) Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the french uveitis network. Arthritis and Rheumatology 68:1522\u20131530. https:\/\/doi.org\/10.1002\/art.39667","journal-title":"Arthritis and Rheumatology"},{"key":"3629_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3410\/M2-13","volume":"2","author":"V Cottin","year":"2010","unstructured":"Cottin V (2010) Update on bioagent therapy in sarcoidosis. F1000 Med Rep 2:13. https:\/\/doi.org\/10.3410\/M2-13","journal-title":"F1000 Med Rep"},{"key":"3629_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10020281","volume":"10","author":"T El Jammal","year":"2021","unstructured":"El Jammal T, Loria O, Jamilloux Y, Gerfaud-Valentin M, Kodjikian L, S\u00e8ve P (2021) Uveitis as an open window to systemic inflammatory diseases. J Clin Med 10:1\u201329. https:\/\/doi.org\/10.3390\/jcm10020281","journal-title":"J Clin Med"},{"key":"3629_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-020-00202-6","author":"F Nicolela Susanna","year":"2020","unstructured":"Nicolela Susanna F, Pavesio C (2020) A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect. https:\/\/doi.org\/10.1186\/s12348-020-00202-6","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"3629_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1185\/03007995.2014.993024","volume":"31","author":"P Brito-Zer\u00f3n","year":"2015","unstructured":"Brito-Zer\u00f3n P, Perez-Alvarez R, Ramos-Casals M (2015) Etanercept and uveitis: Friends or foes? Curr Med Res Opin 31:251\u2013252. https:\/\/doi.org\/10.1185\/03007995.2014.993024","journal-title":"Curr Med Res Opin"},{"key":"3629_CR39","unstructured":"Hashkes PJ, Shajrawi I, Hashkes PJ, Shajrawi I, Hashkes P (2003) Sarcoid-related uveitis occuring during etanercept therapy. vol. 21.."},{"key":"3629_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00408-013-9481-5","volume":"191","author":"SK Lee","year":"2013","unstructured":"Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS et al (2013) Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung 191:565\u2013571. https:\/\/doi.org\/10.1007\/s00408-013-9481-5","journal-title":"Lung"},{"key":"3629_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2015.07.001","volume":"61","author":"CS Foster","year":"2016","unstructured":"Foster CS, Kothari S, Anesi SD, Vitale AT, Chu D, Metzinger JL et al (2016) The ocular immunology and uveitis foundation preferred practice patterns of uveitis management. Surv Ophthalmol 61:1\u201317. https:\/\/doi.org\/10.1016\/j.survophthal.2015.07.001","journal-title":"Surv Ophthalmol"},{"key":"3629_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2217\/imt.13.10","volume":"5","author":"A Jain","year":"2013","unstructured":"Jain A, Singh JA (2013) Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy 5:265\u2013299. https:\/\/doi.org\/10.2217\/imt.13.10","journal-title":"Immunotherapy"},{"key":"3629_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/25785826.2019.1642080","volume":"42","author":"E Hasegawa","year":"2019","unstructured":"Hasegawa E, Takeda A, Yawata N, Sonoda KH (2019) The effectiveness of adalimumab treatment for non-infectious uveitis. Immunol Med 42:79\u201383. https:\/\/doi.org\/10.1080\/25785826.2019.1642080","journal-title":"Immunol Med"},{"key":"3629_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41433-018-0283-0","volume":"33","author":"C McCracken","year":"2019","unstructured":"McCracken C, Yeh S, Jenkins K, Travers C, Stryker D, Tommasello S et al (2019) Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis. Eye (Basingstoke) 33:629\u2013639. https:\/\/doi.org\/10.1038\/s41433-018-0283-0","journal-title":"Eye (Basingstoke)"},{"key":"3629_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejim.2021.05.011","volume":"91","author":"R Fern\u00e1ndez-Ram\u00f3n","year":"2021","unstructured":"Fern\u00e1ndez-Ram\u00f3n R, Gait\u00e1n-Valdiz\u00e1n JJ, S\u00e1nchez-Bilbao L, Mart\u00edn-Varillas JL, Mart\u00ednez-L\u00f3pez D, Demetrio-Pablo R et al (2021) Epidemiology of sarcoidosis in northern Spain, 1999\u20132019: a population-based study. Eur J Intern Med 91:63\u201369. https:\/\/doi.org\/10.1016\/j.ejim.2021.05.011","journal-title":"Eur J Intern Med"},{"key":"3629_CR46","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1136\/bjophthalmol-2018-313356","volume":"103","author":"M Mochizuki","year":"2019","unstructured":"Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA (2019) Revised criteria of international workshop on ocular sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol 103:1418\u20131422. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313356","journal-title":"Br J Ophthalmol"},{"key":"3629_CR47","unstructured":"Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, et al. (2014) The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool WASOG Sarcoidosis Organ Assessment Instrument Investigators*. vol. 13."},{"key":"3629_CR48","doi-asserted-by":"crossref","unstructured":"Lobo A, Barton K, Minassian D, Du Bois R, Lightman S. Visual loss in sarcoid-related uveitis. vol. 31. 2003.","DOI":"10.1046\/j.1442-9071.2003.00666.x"},{"key":"3629_CR49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","volume":"39","author":"E Miserocchi","year":"2020","unstructured":"Miserocchi E, Giuffr\u00e8 C, Cornalba M, Pontikaki I, Cimaz R (2020) JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol 39:847\u2013851. https:\/\/doi.org\/10.1007\/s10067-019-04875-w","journal-title":"Clin Rheumatol"},{"key":"3629_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-013-0409-1","author":"J Pan","year":"2014","unstructured":"Pan J, Kapur M, McCallum R (2014) Noninfectious immune-mediated uveitis and ocular inflammation. Curr Allergy Asthma Rep. https:\/\/doi.org\/10.1007\/s11882-013-0409-1","journal-title":"Curr Allergy Asthma Rep"},{"key":"3629_CR51","first-page":"275","volume":"32","author":"L Riancho-Zarrabeitia","year":"2014","unstructured":"Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J, Oterino A, Sedano MJ, Rueda-Gotor J et al (2014) Anti-TNF-\u03b1 therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review. Exp Rheumatol 32:275\u2013284","journal-title":"Exp Rheumatol"},{"key":"3629_CR52","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","volume":"250","author":"RJ Erckens","year":"2012","unstructured":"Erckens RJ, Mostard RLM, Wijnen PAHM, Schouten JS, Drent M (2012) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe\u2019s Arch Clin Exp Ophthalmol 250:713\u2013720. https:\/\/doi.org\/10.1007\/s00417-011-1844-0","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"3629_CR53","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","unstructured":"D\u00edaz-Llopis M, Salom D, Garcia-De-Vicu\u00f1a C, Cordero-Coma M, Ortega G, Ortego N et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575\u20131581. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.018","journal-title":"Ophthalmology"},{"key":"3629_CR54","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/ICU.0000000000000415","volume":"28","author":"H Kefella","year":"2017","unstructured":"Kefella H, Luther D, Hainline C (2017) Ophthalmic and neuro-ophthalmic manifestations of sarcoidosis. Curr Opin Ophthalmol 28:587\u2013594. https:\/\/doi.org\/10.1097\/ICU.0000000000000415","journal-title":"Curr Opin Ophthalmol"},{"key":"3629_CR55","doi-asserted-by":"crossref","unstructured":"Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster (2007) C Stephen. Infliximab Therapy for the Treatment of Refractory Ocular Inflammatory Disease. vol. 125.","DOI":"10.1001\/archopht.125.7.895"},{"key":"3629_CR56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1185\/030079903125002847","volume":"20","author":"V P\u00e9rez-Guijo","year":"2004","unstructured":"P\u00e9rez-Guijo V, Santos-Lacomba M, S\u00e1nchez-Hern\u00e1ndez M, Castro-Villegas MDC, Gallardo-Galera JM, Collantes-Est\u00e9vez E (2004) Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 20:155\u2013157. https:\/\/doi.org\/10.1185\/030079903125002847","journal-title":"Curr Med Res Opin"},{"key":"3629_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","volume":"42","author":"JR Maneiro","year":"2012","unstructured":"Maneiro JR, Salgado E, Gomez-Reino JJ, Carmona L (2012) Efficacy and safety of TNF antagonists in sarcoidosis: data from the spanish registry of biologics BIOBADASER and a systematic review. Semin Arthritis Rheum 42:89\u2013103. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.12.006","journal-title":"Semin Arthritis Rheum"},{"key":"3629_CR58","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3109\/02713683.2010.486520","volume":"35","author":"V Kakkassery","year":"2010","unstructured":"Kakkassery V, Mergler S, Pleyer U (2010) Anti-TNF-\u03b1 treatment: A possible promoter in endogenous uveitis observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 35:751\u2013756. https:\/\/doi.org\/10.3109\/02713683.2010.486520","journal-title":"Curr Eye Res"},{"key":"3629_CR59","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","volume":"48","author":"BL Adler","year":"2019","unstructured":"Adler BL, Wang CJ, Bui TL, Schilperoort HM, Armstrong AW (2019) Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Semin Arthritis Rheum 48:1093\u20131104. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.10.005","journal-title":"Semin Arthritis Rheum"},{"key":"3629_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/717598","author":"M Cordero-Coma","year":"2014","unstructured":"Cordero-Coma M, Calvo-R\u00edo V, Ad\u00e1n A, Blanco R, \u00c1lvarez-Castro C, Mesquida M et al (2014) Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2014\/717598","journal-title":"Mediators Inflamm"},{"key":"3629_CR61","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2147\/OPTH.S35521","volume":"6","author":"EE Lower","year":"2012","unstructured":"Lower EE, Baughman RP, Kaufman AH (2012) Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 6:1613\u20131618. https:\/\/doi.org\/10.2147\/OPTH.S35521","journal-title":"Clin Ophthalmol"},{"key":"3629_CR62","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1183\/09031936.00224513","volume":"43","author":"NJ Sweiss","year":"2014","unstructured":"Sweiss NJ, Lower EE, Mirsaeidi M, Dudek S, Garcia JGN, Perkins D et al (2014) Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 43:1525\u20131528. https:\/\/doi.org\/10.1183\/09031936.00224513","journal-title":"Eur Respir J"},{"key":"3629_CR63","unstructured":"Lower EE, Sturdivant M, Grate L, Baughman RP, Sturdivant M, Grate L, et al. (2020) Use of third-line therapies in advanced sarcoidosis. vol. 38."},{"key":"3629_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102481","author":"M Leclercq","year":"2020","unstructured":"Leclercq M, Langlois V, Girszyn N, Le Besnerais M, Benhamou Y, Levesque H et al (2020) Comparison of conventional immunosuppressive drugs versus anti-TNF-\u03b1 agents in non-infectious non-anterior uveitis. J Autoimmun. https:\/\/doi.org\/10.1016\/j.jaut.2020.102481","journal-title":"J Autoimmun"},{"key":"3629_CR65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","volume":"13","author":"MA Paley","year":"2019","unstructured":"Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ (2019) Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 13:53\u201355. https:\/\/doi.org\/10.1016\/j.ajoc.2018.12.001","journal-title":"Am J Ophthalmol Case Rep"},{"key":"3629_CR66","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","volume":"27","author":"P Bauermann","year":"2019","unstructured":"Bauermann P, Heiligenhaus A, Heinz C (2019) Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm 27:1232\u20131234. https:\/\/doi.org\/10.1080\/09273948.2019.1605453","journal-title":"Ocul Immunol Inflamm"},{"key":"3629_CR67","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.medcli.2019.10.023","volume":"155","author":"G Espinosa","year":"2020","unstructured":"Espinosa G, Herreras JM, Mu\u00f1oz-Fern\u00e1ndez S, Ruiz G, de Morales JM, Cordero-Coma M (2020) Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. Med Clin (Barc) 155:220. https:\/\/doi.org\/10.1016\/j.medcli.2019.10.023","journal-title":"Med Clin (Barc)"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03629-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03629-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03629-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:05:55Z","timestamp":1766167555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03629-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3629"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03629-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6222092\/v1","asserted-by":"object"}]},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Jorge Javier Gait\u00e1n-Valdiz\u00e1n received grants\/research supports and payment for an expert testimony\/advisory from GSK. Santos Casta\u00f1eda has received grants\/research supports from MSD, Pfizer, and UCB, and had consultation fees\/participation in company-sponsored speaker\u2019s bureau from Lilly, Gedeon-Richter, Janssen, Roche and UCB. Ricardo Blanco received grants\/research supports from AbbVie, MSD, and Roche, and had consultation fees\/participation in company-sponsored speaker\u2019s bureau from AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Sanofi, Lilly and MSD. The following authors, Fabricio Benavides-Villanueva,\u00a0Ra\u00fal Fern\u00e1ndez-Ram\u00f3n, Jos\u00e9 L. Mart\u00edn-Varillas, Armin Mobarak,\u00a0Jos\u00e9 Cifri\u00e1n Mart\u00ednez and Rosal\u00eda Demetrio-Pablo did not declare financial disclosures. Data reported in this manuscript were presented in part at the virtual 2021 EULAR Congress hold in Frankfurt, Germany, 2-5 June 2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"268"}}